These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38528728)

  • 81. Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions.
    Pan W; Yang D; Yu P; Yu H
    BMC Cardiovasc Disord; 2020 Apr; 20(1):208. PubMed ID: 32354356
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
    Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
    Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Myocardial Effects of Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction.
    McDiarmid AK; Swoboda PP; Erhayiem B; Bounford KA; Bijsterveld P; Tyndall K; Fent GJ; Garg P; Dobson LE; Musa TA; Foley JRJ; Witte KK; Kearney MT; Greenwood JP; Plein S
    J Am Heart Assoc; 2020 Jan; 9(1):e011521. PubMed ID: 31852424
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging.
    Park JR; Choi JO; Han HJ; Chang SA; Park SJ; Lee SC; Choe YH; Park SW; Oh JK
    Int J Cardiovasc Imaging; 2012 Apr; 28(4):763-72. PubMed ID: 21516440
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
    Butler J; Hernandez AF; Anstrom KJ; Kalogeropoulos A; Redfield MM; Konstam MA; Tang WH; Felker GM; Shah MR; Braunwald E
    JACC Heart Fail; 2016 Sep; 4(9):726-35. PubMed ID: 27522631
    [TBL] [Abstract][Full Text] [Related]  

  • 87. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
    Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
    Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
    Kosmala W; Rojek A; Przewlocka-Kosmala M; Wright L; Mysiak A; Marwick TH
    J Am Coll Cardiol; 2016 Oct; 68(17):1823-1834. PubMed ID: 27765184
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Correlation between plasma N-terminal pro-brain natriuretic peptide levels and changes in New York Heart Association functional class, left atrial size, left ventricular size and function after mitral and/or aortic valve replacement.
    Elasfar A
    Ann Saudi Med; 2012; 32(5):469-72. PubMed ID: 22871614
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction.
    Kurrelmeyer KM; Ashton Y; Xu J; Nagueh SF; Torre-Amione G; Deswal A
    J Card Fail; 2014 Aug; 20(8):560-8. PubMed ID: 24905296
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Association of Left Atrial Structure and Function With Heart Failure in Older Adults.
    Inciardi RM; Claggett B; Minamisawa M; Shin SH; Selvaraj S; Gonçalves A; Wang W; Kitzman D; Matsushita K; Prasad NG; Su J; Skali H; Shah AM; Chen LY; Solomon SD
    J Am Coll Cardiol; 2022 Apr; 79(16):1549-1561. PubMed ID: 35450571
    [TBL] [Abstract][Full Text] [Related]  

  • 93. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
    Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
    JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Circulating Biomarkers and Cardiac Structure and Function in Rheumatoid Arthritis.
    Kobayashi M; Ferreira MB; Costa RQ; Fonseca T; Oliveira JC; Marinho A; Carvalho HC; Girerd N; Rossignol P; Zannad F; Rodrigues P; Ferreira JP
    Front Cardiovasc Med; 2021; 8():754784. PubMed ID: 34869664
    [No Abstract]   [Full Text] [Related]  

  • 95. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The level of NT-proBNP in ambulatory patients with chronic heart failure with preserved ejection fraction of the left ventricle.
    Kirillova VV; Sokolova LA; Meshchaninov VN; Pershanova VI
    Ter Arkh; 2018 Sep; 90(9):68-72. PubMed ID: 30701738
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Felker GM; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Mark DB; Piña IL; Passmore G; Whellan DJ; Yang H; Cooper LS; Leifer ES; Desvigne-Nickens P; O'Connor CM
    JAMA; 2017 Aug; 318(8):713-720. PubMed ID: 28829876
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
    Anker SD; Butler J; Filippatos G; Shahzeb Khan M; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Seronde MF; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    Eur J Heart Fail; 2020 Dec; 22(12):2383-2392. PubMed ID: 33251670
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization.
    Nikolova AP; Hitzeman TC; Baum R; Caldaruse AM; Agvanian S; Xie Y; Geft DR; Chang DH; Moriguchi JD; Hage A; Azarbal B; Czer LS; Kittleson MM; Patel JK; Wu AHB; Kobashigawa JA; Hamilton M; Hong T; Shaw RM
    JAMA Cardiol; 2018 Dec; 3(12):1206-1210. PubMed ID: 30383171
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy.
    Maron MS; Chan RH; Kapur NK; Jaffe IZ; McGraw AP; Kerur R; Maron BJ; Udelson JE
    Am J Med; 2018 Jul; 131(7):837-841. PubMed ID: 29604289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.